Follow Us On

Facebook  X  Linkedin  YouTube
 
 


Blood thinners are a leading cause of drug-related harm. Can the risk be lowered?


More than 8 million people in the U.S. take blood thinners to prevent dangerous clots. At the same time, the drugs are responsible for a staggering number of serious bleeding events.


According to Dr. Pieter Cohen, an associate professor of medicine at Harvard University, who carried out a recent study on emergency room visits due to blood thinners, the most common issue is bleeding in the stomach or the wider GI tract.


“A bunch of those people need to be hospitalized to stabilize the situation, or they may need a transfusion,” Cohen said. “So that can be very serious. A very swift, massive GI bleed that cannot be stabilized can lead to disability or death.”


People taking anticoagulants can also experience serious bleeds from small cuts or grazes, uncontrolled nosebleeds, blood in the urine and, more rarely, brain hemorrhages or bleeding in the lungs.


Click here to read the full article.

A limited number of qualifying residents/fellows will receive a scholarship to attend the ASIPP 28th Annual Meeting, March 19-21, 2026 at the Hilton New Orleans Riverside. Recipients of this scholarship with receive reimbursement of their meeting registration, and up to three nights stay at the host hotel. This includes room block rate and tax.


Deadline to apply is February 15, 2026


Click here for more information.

Join Us in New Orleans for ASIPP 2026

Earn CMEs, Expand Networks, and Explore the Future of Pain Management

For a limited-time when two full Annual Meeting registrations are completed, two registrations are provided at no additional cost! This special registration offer makes it easier to bring colleagues or members of your staff to the annual meeting.


Group attendance encourages shared learning, stronger collaboration, and a unified approach to implementing best practices in interventional pain management.

JOIN or RENEW your ASIPP Membership for the best registration rates.

 



RESERVE your HOTEL ROOM TODAY!


Discounted room rates end

February 24.

Hands-On Cadaver Workshops

 





Don't miss the Hands-On Cadaver Workshops taking place March 20 and 21 alongside the Annual Meeting in New Orleans!



These workshops offer practical, guided training in key interventional procedures.


This is an invaluable opportunity to sharpen your skills and gain confidence through real-time, instructor-led practice.



  • Peripheral Nerve Stimulation

Sponsored by Curonix 
(non-CME)



  • Minimally Invasive Spine Interventions

(8 CMEs)



  • Spinal Cord Stimulation

(8 CMEs)



  • Regenerative Medicine

(8 CMEs)




  • Interventional Techniques in IPM

(8 CMEs)




 
 

40% OFF

new individual Annual Meeting registrations for a limited time!

 

Be sure to enter code SAVE40 at checkout to save!

Applies to new, individual registrations only.

Offer may not be combined with other discounts.

 

Which Fibromyalgia Drug Offers the Best Value?

Modeling study supports an FDA-approved product over off-label amitriptyline

 

Key Takeaways


• Several different medications may be prescribed for fibromyalgia, including amitriptyline, pregabalin (Lyrica); duloxetine (Cymbalta), and milnacipran (Savella).


• Some are more expensive than others, but dosing and effectiveness vary as well, raising questions as to which is most cost-effective.


• In this modeling study based on published data, duloxetine at 120 mg/day and, to a lesser extent, pregabalin at 450 mg/day appeared superior in cost-effectiveness.

One drug for treating fibromyalgia came out on top in a comparative cost-effectiveness study, researchers said.

 

Published data on drug costs and clinical efficacy for four drugs -- amitriptyline, duloxetine (Cymbalta), pregabalin (Lyrica), and milnacipran (Savella) -- suggested that the best overall value came from 120 mg/day of duloxetine, according to Tewodros Eguale, MD, PhD, of the Massachusetts College of Pharmacy and Health Sciences in Boston, and colleagues.

 

While amitriptyline is relatively cheap and some evidence has indicated that it can be quite effective in fibromyalgia (though not FDA approved for the indication), it fell short in the modeling study, the group reported in JAMA Network Open. Pregabalin at 450 mg/day matched up with 120 mg/day duloxetine in some respects, but the latter appeared superior overall.

 

Click here to read the full article.

Upcoming ASIPP Webinars

Register today!

ASIPP is launching a new webinar series focused on Regenerative Medicine!


Join us on February 11 for the first webinar, complimentary: Integrating Regenerative Medicine into Your Pain Practice: Why, What, and How.



Coffee and Tea May Protect Against Dementia but Hold the Decaf  




Regular consumption of coffee and tea was associated with a lower risk for dementia and modest improvements in cognitive performance, independent of a person’s genetic predisposition, a new study showed.


Results from two large cohorts showed that the benefits were strongest among those with a daily intake of about 2-3 cups of caffeinated coffee or 1-2 cups of tea. These associations remained consistent even when accounting for high-risk genetic factors, including APOE4 genotype and Alzheimer’s disease polygenic risk scores.


“The overall patterns were broadly similar across genetic risk groups, suggesting these behaviors may be relevant across genetic risk levels — not only among people at lower genetic risk,” lead study author Yu Zhang, MBBS, MS, Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Harvard University, Boston, told Medscape Medical News.


Click here to read the full article.

The Opportunity:

  • Well-established group seeking an interventional pain physician with pain fellowship training
  • Comprehensive interventional pain management program with physicians, nurse practitioners, and two Ambulatory Surgery Centers
  • Established interventional pain management practice with strong clinical and research focus
  • High-volume practice that is ethical and fully legally compliant
  • Research and publication opportunities available
  • Early and generous partnership opportunities in both the practice and ASC


The Community:

  • Excellent quality of life in a county of more than 60,000 residents, with a regional drawing area exceeding 200,000
  • High standard of living with abundant recreational and social opportunities
  • Strong public school system and a private parochial elementary school
  • Convenient location: approximately 2.5 hours to Nashville and St. Louis; 3 hours to Memphis, Louisville, and Lexington
  • Daily one-hour flights to major international hubs, including Chicago O’Hare and Houston, TX


Please email Cindy Jackson at cindy@thepainmd.com with your current CV to schedule an interview or to learn more about this practice.

Our Sponsor

ASIPP is pleased to announce the launch of the Regenerative and Longevity Medicine Section!


This section reflects the growing importance of regenerative and longevity medicine—fields dedicated to restoring health, enhancing vitality, and extending the healthy years of life. From stem cell therapies and tissue engineering to gene therapy and orthobiologics, these disciplines are transforming the way we approach pain management and age-related decline.


Section membership offers:

  • Access to ASIPP’s physician database and future data registry
  • Opportunities for certification and continuing education
  • Section-exclusive resources and updates


Click here to apply.

No additional cost for ASIPP members!

ASIPP is proud to launch our Resident and Fellow Mentorship Program. This initiative is designed to connect trainees with experienced pain physicians to foster professional growth, provide guidance, and strengthen the future of our specialty.


Each mentor would be paired with one to two trainees, but can take more if interested. Trainees will be responsible for initiating introductions and arranging at least one to two video calls per year. These sessions will provide opportunities for mentees to seek advice on clinical decision-making, career planning, research opportunities, and professional development.


We believe that your experience, expertise, and insight can have a lasting impact on the next generation of pain physicians. By volunteering as a mentor, you will play a critical role in shaping the future of our field and ensuring that ASIPP continues to cultivate excellence in interventional pain medicine.


If you are interested in serving as a mentor, please confirm your participation by filling out the appropriate form below.



Retention Rates Remain Low for US Opioid Treatment Programs



US opioid treatment programs had low retention rates in 2023, with a median rate of 61% at 30 days, dropping to 27.5% at 180 days, a new study of Medicaid beneficiaries showed. Even at the programs’ peak performance in 2021, the 30-day retention rate was only 65%, highlighting significant room for improvement in patient engagement, the researchers noted.

 

METHODOLOGY:

  • The cohort study included more than 261,000 adult beneficiaries of Medicaid with a primary opioid use disorder diagnosis (mean age, 39 years; 54% men) from June 2018 to December 2023.
  • Opioid treatment program retention rates were evaluated at 30, 90, and 180 days across 5 measurement years (2019-2023).
  • Claims and enrollment information data were obtained from the Centers for Medicare & Medicaid Services Transformed Medicaid Statistical Information System Analytic Files.


Click here to read the full article.

Our Sponsor


AMA Joins Vaccine Review Effort as CDC Trust Plummets

The system has "now effectively collapsed," the AMA said


The American Medical Association (AMA) and the Vaccine Integrity Project announced that they will independently assess vaccine safety and effectiveness for the 2026-2027 respiratory virus season.


This initiative comes as the CDC continues to make a bevy of changes to U.S. vaccine recommendations, including slashing the number of universally recommended childhood vaccines from 17 to 11, contrary to the advice of public health experts.


Trust in the CDC has fallen to an all-time low, according to a KFF poll. In March 2020, 85% of Americans indicated a great deal or fair amount of trust in the public health agency. As of last month, that number has plummeted to 47%.


Click here to read the full article.


Apply now for one of the following dates:


March 14, April 18,

May 23, & June 27, 2026



  • ABIPP Part I

Four (4) hour virtual exam


  • ABIPP Path – Combined CCPM/ CSM Exam

For those with subspecialty in Pain Medicine

Two (2) hour virtual exam


  • ABIPP Competency Exam in IPM

For those without primary board certification

Two (2) hour virtual exam


  • ABIPP Competency Exam in Regenerative Medicine

Two (2) hour virtual exam


  • Controlled Substance Management Competency Exam

Two (2) hour virtual exam


  • Documentation, Coding, Compliance, Practice Management Competency Exam

Two (2) hour virtual exam

Exam Dates

 

We're excited to let you know that the new ASIPP Community, hosted by DocMatter, is now live!


The ASIPP Community on DocMatter will serve as a place for members to collaborate around clinical and research topics to advance the care of their interventional pain patients.


Click here to be a part of the conversation!

Pain Medicine Case Reports (PMCR) and Editor-in-Chief Alaa Abd-Elsayed, MD, PhD would like to invite you to submit case reports and case series to the PMCR journal. Your article will be published free of charge.


Open access journals are freely available online for immediate worldwide open access to the full text of published articles. There is no subscription fee for open access journals. Open access journals are no different from traditional subscription-based journals: they undergo the same peer review and quality control as any other scholarly journal.


Interested in becoming a member of the PMCR Editorial Board?

Editorial board members are asked to review 2-6 manuscripts per year. Please submit your most up-to-date CV to sgold@asipp.org for consideration.


For more information or to submit your articles, click here.

We are excited to announce that Pain Medicine Case Reports (PMCR) journal (eISSN 2768-5152) has been accepted for inclusion in MEDLINE and PubMed, the prestigious bibliographic database of the U.S. National Library of Medicine. PMCR, a companion publication to the prestigious Pain Physician journal by ASIPP, joins its counterpart in achieving indexing in both MEDLINE and PubMed, marking ASIPP’s dual presence in these renowned databases.


The inclusion of PMCR journal in MEDLINE signifies a higher level of selectivity, as MEDLINE consists of the top 5,200 biomedical journals. This indexing also means that articles from PMCR will be searchable using NLM Medical Subject Headings (MeSH terms) and other metadata.


The selection for MEDLINE follows a rigorous evaluation process by reviewers from the Literature Selection Technical Review Committee (LSTRC). According to their criteria, the scientific quality of a journal’s content is the primary factor considered for indexing.


We extend our congratulations to the Pain Medicine Case Reports Editor-in-Chief, Deputy Editor-in-Chief, Journal Team, and Editorial Board for this achievement, which underscores the significance and excellence of this esteemed journal.

 

CASE REPORTS

Spinal Cord Infarction as an Immediate Complication of Spinal Cord Stimulator Placement


Vishveshvar Ramkumar, BS, and Jason Maljaars, MD

Ultrasound-Guided Percutaneous Intercostal Cryoneurolysis for Anterior Cutaneous Nerve Entrapment Syndrome: A Case Report


Kyle F. Norton, MD, Jeffrey L. Chen, MD, Nicole Xu, BS, Igor Filipovski, MD, and Rodney A. Gabriel, MD

 
 

New Issue!

 

RANDOMIZED CONTROLLED TRIALS

Thoracic Intervertebral Foramen Blocks Compared to Midpoint-to-Pleura Transverse Process Blocks for the Management of Acute Rib Fracture Pain


Barbara Pizzi, MD, Vincenza Cofini, MD, Emiliano Petrucci, MD, Stefano Necozione, MD, and Franco Marinangeli, MD, PhD

Early Evaluation of Thermal Radiofrequency vs. Chemical Neurolysis for T2 and T3 Sympathectomy in Post-Mastectomy Pain Syndrome Using Oximetry-Based Perfusion Index Assessment


Walaa Y. Elsabeeny, MD, Mahmoud S. Soliman, MD, Taher S. Thabet, MD, and Sayed M. Abed, MD

Effects of Continuous Intercostal Nerve Block Versus Patient-Controlled Intravenous Analgesia on Postoperative Pain After Video-Assisted Thoracoscopic Surgery


Zhou Zangong, Master, Song Jianfang, MD, Jin Xiangfeng, MD, PhD, Zhao Lipeng, Master, Luo Yiren, MD, Shi Caifeng, Master, Zhou Haiqing, Master, and Liu Shanling, MD, PhD

OBSERVATIONAL STUDY

Ultrasound-guided Pulsed Radiofrequency at the C2 Level for Cervicogenic Headache: Targeting the Greater Occipital Nerve


Sukriye Dadali, MD, Seref Celik, MD, Gulcin Babaoglu, MD, Ulku Sabuncu, MD, Ali Costu, MD, Saziye Sahin, MD, and Erkan Yavuz Akcaboy, MD




ASIPP is in collaboration with Curi Medical Liability Program




Since this malpractice insurance program officially launched in November 2018, ASIPP has signed up hundreds of providers with an average savings of 30%. This is professional liability insurance tailored to our specialty and will stand up for us and defend our practices. 

 

Curi is a full-service advisory firm that serves physicians and their practices. Their valued advice is grounded in your priorities and elevated in your outcomes. They are driven by a deep understanding of your specific circumstances in medicine, business, and life. To read a few important points to keep in mind about the program, including discounts, administrative defense, cyber coverage, aggressive claims handling, and complimentary risk management CME activities, visit our website.



IMPORTANT UPDATE

SPRINT no longer classified as PNT 



SPR is happy to announce an important update regarding Humana Medicare Advantage. As of May 1, Humana is now recognizing SPRINT as a PNS therapy. Previously, SPRINT was categorized as PNT (Percutaneous Nerve Stimulation), which allowed denials on the grounds that the therapy fell outside the NCD.


Additional details are as follows:

Payer: Humana Medicare Advantage (click here to view policy)

Policy Title: Peripheral Nerve Stimulators

Policy changes: SPRINT no longer misclassified as PNT and is now appropriately classified as PNS. Humana is applying the Noridian Medicare LCD criteria to ALL PNS devices – Including SPRINT PNS!

Effective Date: 5/1/2025


Click here to view a PDF of the official policy update.

 

Group Purchasing Organization Offer Better Pricing and Creates Added Value


ASIPP has formed a partnership with Henry Schein and PedsPal, a national GPO that has a successful history of negotiating better prices on medical supplies and creating value-added services for independent physicians. Working with MedAssets, PedsPal provides excellent pricing on products like contrast media that alleviate some of the financial pressures you experience today.



Learn More


For updated information concerning tariffs on products, click here.

 
 

ASIPP, Fedora Healthcare Solutions Partnership


ASIPP offers our members the benefit of a unique revenue cycle management/ billing service.



We have received a tremendous amount of interest in the ASIPP billing and coding program.




Click here to learn more about the negotiated rate for practices and more!

Like and Follow ASIPP® on Facebook, X, LinkedIn,

and YouTube for the most up-to-date news

related to you, your practice, and your patients!